2020年業績（2020年１月～12月）

 

I. 著書および論文
①著書
1. 寺尾岳, 牧野麻友. 抗不安薬.「PocketDrugs2020」pp12-19.医学書院,東京. 2020.

2. 寺尾岳(編・著), 井上幸紀(著), 松永寿人(著), 吉村玲児(著). 精神科とは無縁と思っていたあなたが困ったときに精神科を味方につけるための本.星和書店,東京. 2020.

3. 寺尾岳. 双極症の薬物療法(Topicsサングラス療法―双極症の新しい補完的治療).精神疾患の臨床1気分症群.296-308.中山書店,東京. 2020.

4. 寺尾岳(編). 双極性障害に投与する薬.精神科薬物療法に再チャレンジ.61-84.星和書店,東京. 2020.

②原著
1. Mari Akase, Takeshi Terao, Nobuko Kawano, Akari Sakai, Koji Hatano, Masanao Shirahama, Hirofumi Hirakawa, Kentaro Kohno, Nobuyoshi Ishii. More Purpose in Life and Less Novelty Seeking Predict Improvements in Self-Compassion During a Mindfulness-Based Intervention: The EXMIND Study. Front Psychiatry.11:252. 2020.

2. Masumi Tachibana, Tasuku Hashimoto, Mami Tanaka, Hiroyuki Watanabe, Yasunori Sato, Takashi Takeuchi, Takeshi Terao, Shou Kimura, Akio Koyama, Sachie Ebisawa, Yuichiro Shizu, Teruyoshi Nagase, Junichi Hirakawa, Kotaro Hatta, Michiko Nakazato, Masaomi Iyo. Patterns in Psychiatrists’ Prescription of Valproate for Female Patients of Childbearing Age With Bipolar Disorder in Japan: A Questionnaire Survey. Front Psychiatry.11:250. 2020.

3. Naomi Kozaka, Shouhei Takeuchi, Nobuyoshi Ishii, Takeshi Terao, Yoshiki Kuroda. Association between lithium in tap water and suicide mortality rates in Miyazaki Prefecture. Environ Health Prev Med.25:26. 2020.

4. Kentaro Kohno, Nobuyoshi Ishii, Hirofumi Hirakawa, Takeshi Terao. Lithium in drinking water and crime rates in Japan: cross-sectional study. BJPsych Open.6:e122. 2020.

③症例報告
1. Hirofumi Hirakawa, Takeshi Terao, Nobuyoshi Ishii. A Case of Facial Pain in Somatic Symptom Disorder Responding to Duloxetine. J Clin Psychopharmacol.40:512-513.2020.

2. Hirofumi Hirakawa, Takeshi Terao, Masaaki Muronaga, Nobuyoshi Ishii. Human leukocyte antigen-DRB1*04:05 might be associated with the development of clozapine-induced agranulocytosis in a Japanese patient with schizophrenia. Aust N Z J Psychiatry.54:542-543.2020.

3. 石井啓義, 平川博文, 寺尾岳. 私のカルテから「薬剤性認知障害」.九州神経精神医学.66巻1号:27-29.2020.

④総説
1. Takeshi Terao, Nobuyoshi Ishii, Hirofumi Hirakawa, Eiji Aoshima. Is the Bell-Shaped Dose-Response Curve of the Selective Serotonin Reuptake Inhibitor Due to 5-HT 1A Auto-Receptors?. Med Hypotheses. 140:109681. 2020.

2. Takeshi Terao, Nobuyoshi Ishii, Hirofumi Hirakawa. A specific group of patients with diagnostic conversion from depression to bipolar disorder and finally to dementia as a mental GSK-3 disease: a hypothesis. Bipolar Disord.22:356-359. 2020.

3. Hirofumi Hirakawa, Takeshi Terao, Masaaki Muronaga, Nobuyoshi Ishii. Adjunctive bright light therapy for treating bipolar depression: A systematic review and meta-analysis of randomized controlled trials. Brain Behav.10:e01876. 2020.

3. 寺尾岳. 双極性障害の影響を考慮したアプローチ.週刊医学のあゆみ.272:396-400. 2020.

4. 寺尾岳. 気分変調症の薬物療法(特集Ⅰ気分変調症(持続性抑うつ障害)の臨床).月刊精神科.36:143-148. 2020.

5. 寺尾岳. 極性分類と薬物療法.精神科診断学.13:122-126. 2020.

6. 寺尾岳. 双極性障害と攻撃性.精神神経雑誌.122:194-201. 2020.

7. 寺尾岳. 日本うつ病学会治療ガイドラインⅠ双極性障害2017.精神医学.62:560-566. 2020.

8. 寺尾岳. 生活習慣・環境とメンタルヘルス.臨床精神薬理.23:663-667. 2020.

9. 平川博文, 石井啓義, 寺尾岳. 環境光とメンタルヘルス.臨床精神薬理.23:669-674. 2020.

10. 石井啓義, 河野健太郎, 平川博文, 寺尾岳. 水道水リチウムとメンタルヘルス.臨床精神薬理.23:705-712. 2020.

11. 石井啓義, 平川博文, 寺尾岳. 微量なリチウムと衝動性.最新精神医学.25:287-291. 2020.

12. 寺尾岳. Ⅳ双極性障害の治療-双極性障害の薬物療法「炭酸リチウム」.日本臨牀.78:1683-1688. 2020.

⑤レター等（その他）
1. Hirofumi Hirakawa, Nobuyoshi Ishii. Abortion and suicide attempt. Lancet Psychiatry. 7:236-237. 2020.

2. Hirofumi Hirakawa, Nobuyoshi Ishii. Depression as a Factor in Nonadherence in Schizophrenia. J Clin Psychiatry.81. 2020.

3. Kentaro Kohno, Takeshi Terao, Hirofumi Hirakawa, Nobuyoshi Ishii. Bell-shaped dose-response curve of antipsychotic drugs and dopaminergic auto-receptors:a hypothesis. Clinical Neuropsychopharmacology and Therapeutics.11:47-48, 2020.